Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-12-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司与认购对象签署附条件生效的股份认购合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a conditional share subscription agreement between Kunming Pharmaceutical Group Co., Ltd. and a subscribing party. It details the terms of a non-public share issuance, including the number of shares, pricing, payment, lock-up period, and conditions for effectiveness. The document is a formal announcement of a capital raising transaction through a private placement of shares, including contractual terms and regulatory approvals required. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update about a share issuance agreement. The document length is about 4,078 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-12-29 Chinese
北京华方科泰医药有限公司审计报告及财务报表（2013年1月1日至2014年10月31日止）
Audit Report / Information Classification · 100% confidence The document is an audit report issued by Da Hua Certified Public Accountants for Beijing Huafang Ketai Pharmaceutical Co., Ltd. It includes detailed financial statements such as consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in shareholders' equity for the periods ending December 31, 2013, and October 31, 2014. The text contains the auditor's responsibilities, management's responsibilities, and the auditor's opinion on the financial statements. The presence of detailed financial data and the auditor's opinion indicates this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters), and it contains the full audit opinion and financial statements, not just a notice or certification. Therefore, the appropriate classification is Audit Report / Information (AR). Q3 2014
2014-12-29 Chinese
非公开发行股票之募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report about a non-public stock issuance by Kunming Pharmaceutical Group Co., Ltd. It includes extensive information on the use of raised funds, acquisition plans, financial data, business strategy, and impact on company structure and finances. The content focuses on the feasibility analysis of the fundraising and investment projects, including acquisition of assets, expansion projects, and working capital supplementation. It contains financial figures, strategic rationale, and detailed project descriptions, indicating it is a comprehensive financial and strategic report rather than a brief announcement or a simple regulatory filing. The document length (over 13,000 characters) and the depth of financial and operational details confirm it is not a mere announcement or certification. Therefore, this document fits the category of a Capital/Financing Update (CAP), as it provides an update on the company's fundraising activity and the planned use of proceeds in detail.
2014-12-29 Chinese
收购股权涉及的北京华方科泰医药有限公司股东全部权益评估项目资产评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for Beijing Holley-Cotec Pharmaceutical Co., Ltd., commissioned by Kunming Pharmaceutical Group Co., Ltd. It includes extensive financial data, company background, valuation methods (asset-based and income approach), and a valuation conclusion dated October 31, 2014. The report is prepared by a registered asset appraisal firm and includes audited financial statements and detailed analysis of subsidiaries and business operations. The content is consistent with an asset valuation or appraisal report rather than a general annual report or earnings release. It is not a brief announcement or a certification letter but a comprehensive valuation report with substantive financial data and analysis. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit and valuation reports and applied accounting principles, excluding full annual reports. 9M 2014
2014-12-29 Chinese
关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding amendments to the company's articles of association (公司章程). It details specific changes to governance provisions, shareholder meeting powers, profit distribution policies, and other corporate governance matters. The document references compliance with Chinese regulatory guidelines such as the China Securities Regulatory Commission's Listing Company Regulatory Guidelines and the Listing Company Shareholder Rules. The content is focused on governance structure and rules rather than financial results or audit opinions. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal announcement of changes to the company's governance documents, which fits the category of Governance Information (CGR). The document length (7,919 characters) and detailed content support this classification with high confidence.
2014-12-29 Chinese
关于取消2014年第四次临时股东大会的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the cancellation of the company's 2014 fourth extraordinary general meeting of shareholders. It details the background of the meeting notice, reasons for cancellation related to the company's non-public stock issuance planning and stock suspension, and the subsequent handling of the agenda items. The document is short (1335 characters) and serves as a formal notice about a shareholder meeting cancellation rather than the meeting materials or voting results themselves. It does not contain financial statements or detailed financial data. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to shareholder meeting agenda and voting matters, specifically the cancellation of a meeting and the handling of its agenda.
2014-12-25 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.